Biodexa Pharmaceuticals (BDRX) announced the closing of an exclusive license with Otsuka Pharmaceutical for OPB-171775. a novel molecular glue intended to be developed for the treatment of gastrointestinal stromal tumours, GIST. The compound also has the potential to be useful in additional indications. In Biodexa’s pipeline, OPB-171775 is to be coded MTX240.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals Names Fiona Sharp CFO and Board Director
- Biodexa Pharmaceuticals Promotes Fiona Sharp to CFO and Board Director
- Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary
- Biodexa Pharmaceuticals Prices $10 Million U.S. Public Offering to Fund Pipeline
- Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering